Clinical Trials Logo

Bacteremia Sepsis clinical trials

View clinical trials related to Bacteremia Sepsis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05002413 Completed - Bacteremia Sepsis Clinical Trials

Nanomotion-based Resistell AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia and/or Sepsis

NANO-RAST
Start date: June 18, 2021
Phase:
Study type: Observational

Blood culture samples from bacteremia patients positive for Gram-negative bacteria will be tested for antibacterial susceptibility using Resistell Phenotech device. The results will be compared with current AST gold standard tests to calculate sensitivity, specificity, and accuracy of Resistell Phenotech device.

NCT ID: NCT03876990 Completed - Fungemia Clinical Trials

Clinical and Medico-economic Evaluation of a Rapid Test (ePlex-BCID®, GenMark) for the Diagnosis of Bacteremia and Fungemia.

HEMOFAST
Start date: June 20, 2019
Phase: N/A
Study type: Interventional

This study evaluates the clinical benefit of a rapid test for fast diagnosis of bacteremia and fungemia from positive blood cultures in case of sepsis. This assay enables rapid identification of bacteria and fungi and allows to evaluate bacterial resistance to first line antibiotics. The clinical and medico-economic impact of this assay used in addition to the current diagnosis strategy (half of the patients) will be compared to the current diagnostic strategy alone (other half of the patient).

NCT ID: NCT03611257 Completed - Clinical trials for Hematologic Diseases

Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether the use of direct rapid antibiotic susceptibility test (dRAST), in addition to the current standard antibiotic susceptibility test, can increase the proportion of patients with hematologic disease who received appropriate antibiotics in early period of bacteremia.

NCT ID: NCT03577366 Completed - Bacteremia Sepsis Clinical Trials

Prevalence and Characterization of Diagnostic Error Among Patients With Bacteremia

Start date: January 1, 2016
Phase:
Study type: Observational

Diagnostic error is an important but often under-recognized source of adverse events in the hospital. This study is focused on the delayed or missed diagnosis of sepsis associated with bacteremia among patients admitted to The Ottawa Hospital. The aim of this study is to determine the prevalence and characterization of diagnostic error among patients admitted to the at The Ottawa Hospital with sepsis associated with a positive blood culture. This study will consist of a retrospective chart review of all patients who are greater than 18 years with positive blood culture taken within 12 hours of presenting to the Emergency Department of Ottawa Hospital Civic and General Campus between January 2016 to August 13th 2017. For charts that are eligible for review for diagnostic errors, the qSOFA (Quick Sequential [Sepsis-related] Organ Failure Assessment) score at time at admission will be used to identify those patients who were at risk of serious harm because of a missed diagnosis of sepsis and lack of treatment. Patient variables will be collected and compared between the following three groups: (1) patients who received antibiotics within 24 hours, (2) patients who did not receive antibiotics within 24 hours and who did not meet qSOFA criteria, and (3) patients who did not receive antibiotic within 24 hours and who met qSOFA criteria. Variables to be studied include age, gender, hospital campus, admitting service, day of admission (weekend vs. weekday), time of admission (night vs. day), length of stay, disposition and Elixhauser Comorbidity Index. For charts eligible for review for diagnostic error, the DEER (Diagnostic Error Evaluation Research) Taxonomy tool will be used to classify cases per the location and type of error that occurred in the diagnostic process.